Acrivon Therapeutics (ACRV) revenue and earnings history
Acrivon Therapeutics's annual figures for 5 fiscal years, as filed with the SEC.
Revenue and net income, 5 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Dec 31, 2025 | — | −$84.1M | −$77.9M | −$63.7M | $1.67M | −$65.3M | $14.7M | — | — | $41.5M | — | 10-K |
| 2024ended Dec 31, 2024 | — |
The latest quarter, insider trades and fund moves: Acrivon Therapeutics (ACRV) on OQRO.
Common questions
Has Acrivon Therapeutics been profitable?
It reported a net loss in 5 of the years shown (2021, 2022, 2023, 2024, 2025). The highest net income was −$16.2M in fiscal 2021.
What was Acrivon Therapeutics's free cash flow in fiscal 2025?
−$65.3M: operating cash flow of −$63.7M minus capital expenditure of $1.67M. OQRO calculates free cash flow this way from the two filed lines.
Does Acrivon Therapeutics buy back shares or pay dividends?
None of the 5 annual reports shown tags a share buyback or a dividend payment in the standard US taxonomy.
Why is earnings per share not in this table?
Where these figures come from
The SEC’s companyfacts data: every figure Acrivon Therapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.